Dr Georgina Barnett

Project Coordinator, University of Leicester

BSc (Hons) Biology, University of Nottingham, 1993
MSc in Molecular Pathology & Toxicology, University of Leicester, 1995
PhD, University of Nottingham, 1999

Tel. 0116 2044788
Email: gb183@le.ac.uk

College of Life Sciences, University of Leicester

Current Role

My current role is based in the College of Life Sciences, supporting the College Athena SWAN application as part of the CLS Athena SWAN Delivery Team.

Research Interests

Up to 30% of patients with chronic total occlusion (CTO) of the coronary artery are ineligible for revascularization by conventional angioplasty. Therapeutic enhancement of the collateral circulation may offer a novel solution for the treatment of CTO in these cases.

My recent research, with Professor Tony Gershlick investigates the use of prolyl hydroxylase inhibitors to target a pro-angiogenic ‘masterswitch’, the transcription factor Hypoxia Inducible Factor-1α (HIF-1α), with the aim of stimulating a local angiogenic signalling cascade to enhance collateral vasculature and antegrade blood flow and thus provide symptom relief for difficult CTO.

Key areas of research:

  • Endothelial cell biology and angiogenesis
  • Novel drug delivery approaches for controlled, local release
  • Key Publications

    Conference Abstracts

    Barnett, GA, Al-Lamee K, Schofield, CJ, Egginton S, Gershlick AH. Pro-angiogenic effects of proly-hydroxylase inhibitors and their potential for use in a novel strategy of therapeutic angiogenesis for coronary total occlusion. Presented at ESC Frontiers in Cardiovascular Biology, 2016.

    Barnett GA, Schofield CJ, Al-Lamee K, Casaretto M, Arndt S, Egginton S, Gershlick AH. Angiogenesis as a Therapeutic Option for Untreatable CTO. Heart. 2016; 102:Suppl 4 A2 (Shortlisted (as 1 of 3) for Young Investigators Award, British Cardiovascular Intervention Society, Advanced Cardiovascular Medicine Meeting, January 2016) (Oral presentation).

    Barnett G, Kelly D, Flashman E, Schofield C, Gershlick A. Pro- angiogenic effects of Prolyl-Hydroxylase Inhibitor FG-2216 and Potential for Use in a Novel Strategy of Therapeutic Angiogenesis for Difficult Cases of Coronary Total Occlusion. Angiogenesis 2014: 17.1. P-33 DOI 10.1007/s10456-014-9425-6 (Presented at 5th International Meeting on Angiogenesis March 2014, Amsterdam).

    Journal Papers

    MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 2002; 21(44): 6809-18.

    Murray JC, Barnett G, Tas M, Jakobsen A, Brown J, Powell D, Clelland C. Immunohistochemical analysis of endothelial-monocyte activating polypeptide-2 in vivo. American Journal of Pathology. 2000; 157: 2045-2053.

    Barnett G, Jakobsen AM, Tas M, Rice K, Carmichael J, Murray JC. Prostate adenocarcinoma cells release the novel pro-inflammatory polypeptide EMAP-2 in response to stress. Cancer Research. 2000; 60: 2850-2857.


    Department of Cardiovascular Sciences










    Share this page: